
(Jb Reed/Bloomberg News)
A Food and Drug Administration advisory panel recommended yesterday that the diabetes drug Avandia be allowed to remain on the market despite a variety of studies that show it poses elevated risks of heart attack. (Full article: 996 words)
Purchase an electronic copy of the full article. Learn More